Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T13:34:01.077Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of clozapine in treatment-resistant psychosis and neuroleptic sensitivity: results of the Dutch open multi-center project

Published online by Cambridge University Press:  16 April 2020

WMA Verhoeven ,
WH Doesburg ,
R Snoej ,
AJMP Rutgers  and
PHM van Dongen
WMA Verhoeven
Affiliation:
Vincent van Gogh Institute for Psychiatry, Department of Biological Psychiatry, Stationsweg 46, 5803 AC, Venray
WH Doesburg
Affiliation:
Department of Medical Statistics, University Nijmegen Kapittelweg 54, 6525EP, Nijmegen
R Snoej
Affiliation:
Vincent van Gogh Institute for Psychiatry, Department of Biological Psychiatry, Stationsweg 46, 5803 AC, Venray
AJMP Rutgers
Affiliation:
Psychiatric Hospital Vogelenzang, Rijksstraatweg 113, 2125AD, Bennebroek
PHM van Dongen
Affiliation:
Psychiatric Hospital Coudewater, Berlicumseweg 8, 5248NT, Rosmalen, The Netherlands
Get access

Summary

In an open multi-center study, 57 schizophrenic patients were treated with clozapine for indications of treatment-resistant psychosis or severe extrapyramidal side-effects caused by conventional neuroleptics. In 58% of the patients a clinical relevant improvement, expressed as percentage reduction of at least 50 from baseline BPRS scores was observed. With respect to extrapyramidal side-effects, a marked reduction was found upon treatment with clozapine. No major side-effects occurred, particularly agranulocytosis. It was concluded that clozapine is a potent antipsychotic agent that can be used safely when treatment is accompanied by frequent clinical and hematological monitoring.

Keywords

clozapineschizophreniatreatment-resistant psychosis
Type
Original article
Information
European Psychiatry , Volume 7 , Issue 2 , 1992 , pp. 77 - 84
Copyright
Copyright © Elsevier, Paris 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alphs, LDMeltzer, HYBastani, BRamirez, LF (1991) Side effects of clozapine and their management Pharmacopsychiatry 24, 46Google ScholarPubMed
Burki, HREichenberger, ESayers, ACWhite, TG (1975) Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal Pharmacopsychiatry 8, 115–121CrossRefGoogle ScholarPubMed
Chaumet-Riffaud, PD (1991) Clozapine. La prise en charge du risque hématologique L'Encéphale 17, 165–169Google Scholar
Claghorn, JHonigfeld, GAbuzzahab, FSWang, RSteinbook, RTuason, VKlerman, G (1987) The risk and benefits of clozapine versus chlorpromazine J Clin Psychopharmacol 7 377–384CrossRefGoogle ScholarPubMed
Conley, RRSchulz, SCBaker, RWCollins, JFBell, JA (1988) Clozapine efficacy in schizophrenic nonresponders Psychopharmacol Bull 24, 269–274Google ScholarPubMed
Dossing, MAndreason, PB (1986) Diagnoses of acute drug-induced liver injury; usefulness of clinicopathological pattern and biochemical indices Medical Toxicol 1, 77–82CrossRefGoogle Scholar
DSM III (1980) Diagnostic and Statistical Manual of Mental Disorder The American Psychiatric AssociationGoogle Scholar
Griffith, RWSaameli, K (1975) Clozapine and agranulocytosis Lancet ii, 657CrossRefGoogle Scholar
Guy, W (1976) ECDEUAssessment Manual for Psychopharmacology Revised. US Department of Health, Education, and Welfare, DHEW Publ No (ADM), 217–222Google Scholar
Haller, EBinder, RL (1990) Clozapine and seizures Am J Psychiatry 147, 1069–1071Google ScholarPubMed
Herrling, PL (1991) Mechanism of action of atypical antipsychotics Pharmacopsychiatry 24, 48–49Google ScholarPubMed
Honigfeld, GPatin, J (1989) Predictors of response to clozapine therapy Psychopharmacol Berlin 99, S64–S67CrossRefGoogle ScholarPubMed
Honigfeld, GPatin, JSinger, J (1984) Clozapine: antipsychotic activity in treatment-resistant schizophrenics Adv Therapy 1, 77–96Google Scholar
Itil, TMSoldatos, C (1980) Epileptogenic side effects of psychotropic drugs: practical recommendations JAMA 244, 1460–1463CrossRefGoogle ScholarPubMed
Kane, JMHonigfeld, GSinger, JMeltzer, H (1988) The Clozaril collaborative study group Arch Gen Psychiatry 15, 789–796CrossRefGoogle Scholar
Kay, SRFiszbein, AOpler, LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia Schizophrenia Bull 13, 261–276CrossRefGoogle Scholar
Kuha, SMiettinen, E (1986) Long-term effect of clozapine in schizophrenia; a retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years Nord Psykiat T 40, 225–230Google Scholar
Leppig, MBosch, BNaber, DHippius, H (1989) Clozapine in the treatment of 121 out patients Psychopharmacol Berlin 99, S77–S79CrossRefGoogle ScholarPubMed
Lieberman, JAJohns, CAKane, JMRai, KPisciotta, AVSaltz, BLHoward, A (1988) Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs J Clin Psychiatry 49, 271–277Google ScholarPubMed
Lieberman, JAKane, JMJohns, C (1989a) Clozapine: guidelines for clinical management J Clin Psychiatry 50, 329–338Google Scholar
Lieberman, JAJohns, CCooper, TPollack, SKane, JM (1989b) Clozapine pharmacology and tardive dyskinesia Psychopharmacol Berlin 99, S54–S59CrossRefGoogle Scholar
Lindstrom, LH (1988) The effect of long-term treatment with clozapine in schizophrenia - a retrospective study in 96 patients treated with clozapine for up to 13 years Acta Psychiatr Scand 77, 524–529CrossRefGoogle ScholarPubMed
Meltzer, HY (1990) Presynaptic receptors; relevance to psychotropic drug action in man Ann NY Acad Sci 604, 353–371CrossRefGoogle ScholarPubMed
Meltzer, HYBastani, BYoung Kwon, KRamirez, LFBurnett, SSharpe, J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients Psychopharmacol Berlin 99, S68–S72CrossRefGoogle ScholarPubMed
Naber, DLeppig, MGrohmann, RHippius, H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients Psychopharmacol Berlin 99, S73–S76CrossRefGoogle ScholarPubMed
Overall, JEGorham, DR (1962) The Brief psychiatric rating scale Psychol Rep 10, 799–812CrossRefGoogle Scholar
Overall, JEGorham, DR (1976) BPRS: Brief psychiatric rating scaleIn: ECDEU Assessment Manual for Psychopharmacology (Guy, W, ed) Red ed Rockville, MDNational Institute of Mental Health, 157–169Google Scholar
Owen, RRBeake, BJMarby, DDessain, ECCole, JO (1989) Response to clozapine in chronic psychotic patients Psychopharmacol Bull 25, 253–256Google ScholarPubMed
Panteleeva, GPKovskaya, TBelyaev, BSMinker, EIVynar, OSvetska, JLibiger, JKorinkova, VNovotny, VFilip, V (1987) Clozapine in the treatment of schizophrenic patients: an international multicentre trial Clin Ther 10, 57–86Google Scholar
Seen, HJJungi, WFKunz, HPoldinger, W (1977) Clozapine and agranulocytosis Lancet i, 547CrossRefGoogle Scholar
Schmutz, JEichenberger, E (1982) ClozapineIn: Chronicles of Drug Discovery (Bindra, JSLednicer, D, eds) I John Wiley and Sons, Inc, New York, 39–59Google Scholar
Simpson, GMAngus, JW (1970) A rating scale for extrapyramidal side effects Acta Psychiatr Scand 45, S 212, 11–19CrossRefGoogle Scholar
Small, JGMilstein, VMarhenke, JDHall, DDKellams, JJ (1987) Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatmentresistant psychosis J Clin Psychiatry 48, 263–267Google Scholar
Zaccara, GMuscas, GCMessori, A (1990) Clinical features, pathogenesis and management of drug-induced seizures Drug Safety 5, 109–151CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.